B
BridgeBio
Focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform
At a glance
- Status
- Listed
- Listing
- IPO 2019
Open roles
BridgeBio in the Palo Alto ecosystem
The BridgeBio office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later11 investors entered at this stage
- VIViking Global Investors
Cormorant Asset Management- HCHercules Capital
Sequoia- AGAmerican International Group
- CLCORMORANT CAPITAL STRATEGIES LIMITED
KKR- ACAisling Capital
Qatar Investment Authority- AIAIG Investments
Perceptive Advisors
Source: Dealroom Talent Intelligence.
Patents
61 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Investments and acquisitions
Disclosed deals where BridgeBio was the backer or acquirer, 2014–2024. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
7 deals across BridgeBio's capital deployment.
Where the deals concentrate by sector, stage, and decade.
Where BridgeBio deploys vs peers
Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.
BridgeBio's portfolio, mapped.
See BridgeBio on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
BridgeBio readies potential first LGMD2I/R9 therapy as FDA decision on BBP-418 nears
BridgeBio's encaleret shows broad symptom gains in Phase 3 CALIBRATE; next trial underway
Lionsbridge takes $704K stake in BridgeBio Pharma as analysts turn bullish
